Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Nektar Therapeutics Class Action Lawsuit
Business class action lawsuit

Nektar Therapeutics Class Action Lawsuit

Analysis based on 30 articles · First reported Apr 07, 2026 · Last updated May 07, 2026

Sentiment
-70
Attention
4
Articles
30
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The class action lawsuit against Nektar Therapeutics, alleging misleading statements about its REZOLVE-AA trial, has negatively impacted the company's stock price. This event highlights the risks associated with clinical trial integrity and corporate disclosures in the biotechnology sector, potentially leading to increased scrutiny from investors and regulators on similar companies.

Biotechnology Legal Services
Event Summary

Pomerantz LLP, Rosen Law Firm, and The Gross Law Firm have filed and are encouraging investors to join a class action lawsuit against Nektar Therapeutics. The lawsuit alleges that Nektar Therapeutics made materially false and misleading statements regarding its REZOLVE-AA trial for rezpegaldesleukin, a treatment for alopecia areata. Specifically, the company allegedly failed to disclose that enrollment in the trial did not follow applicable instructions and protocol standards, which negatively impacted the trial's results. When Nektar Therapeutics announced on December 16, 2025, that the trial failed to reach statistical significance, its stock price fell by 7.77%. The class period for the lawsuit is from February 26, 2025, to December 15, 2025, and the deadline for investors to seek lead plaintiff appointment is May 5, 2026.

Key Actions
100 Pomerantz LLP filed class action lawsuit Nektar Therapeutics
95 Nektar Therapeutics fell
84 Nektar Therapeutics made misleading statements
70 Rosen Law Firm filed lawsuit Nektar Therapeutics
Entities Involved
stock
Nektar Therapeutics
Nektar Therapeutics is the defendant in a class action lawsuit alleging misleading statements regarding its REZOLVE-AA trial, which led to a significant drop in its stock price.
Importance 100 Sentiment -70
priv
Pomerantz LLP
Pomerantz LLP filed the class action lawsuit against Nektar Therapeutics on behalf of investors, seeking to recover damages.
Importance 90 Sentiment 35
priv
Rosen Law Firm
Rosen Law Firm is another investor rights law firm encouraging Nektar Therapeutics shareholders to join the class action lawsuit and secure counsel.
Importance 70 Sentiment 20
govactor
United States — United States District Court for the Northern District of California
The United States — United States District Court for the Northern District of California is the venue where the class action lawsuit against Nektar Therapeutics was filed.
Importance 50 Sentiment 0
per
Philip Kim
Philip Kim, an attorney at Rosen Law Firm, is a contact person for investors interested in joining the class action lawsuit against Nektar Therapeutics.
Importance 40 Sentiment 30
per
Lawrence Rosen
Lawrence Rosen, founding partner of Rosen Law Firm, is recognized for his work in securities class actions, including the lawsuit against Nektar Therapeutics.
Importance 40 Sentiment 30
per
Danielle Peyton
Danielle Peyton is a contact person at Pomerantz LLP for investors interested in joining the class action lawsuit.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.